Noopept

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Noopept
Noopept.svg
Noopept.png
Systematic (IUPAC) name
Ethyl 1-(phenylacetyl)-L-prolylglycinate
Clinical data
Legal status
  • US: Not FDA approved. Unscheduled
Identifiers
CAS Number 157115-85-0 YesY
PubChem CID: 180496
ChemSpider 157065 N
Synonyms N-Phenylacetyl-L-prolylglycine ethyl ester
Chemical data
Formula C17H22N2O4
Molecular mass 318.367 g/mol
  • c2ccccc2CC(=O)N1CCC[C@@H]1C(=O)NCC(=O)OCC
  • InChI=1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)/t14-/m0/s1 N
  • Key:PJNSMUBMSNAEEN-AWEZNQCLSA-N N
 NYesY (what is this?)  (verify)

Noopept (Russian: Ноопепт; GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. The registered brand name Noopept (Ноопепт) is trademarked by the manufacturer JSC LEKKO Pharmaceuticals. The compound is patented in both the US and Russia with patent of Russian Federation number 2119496, US Patent number 5,439,930 issued 8/8/1995.[1] It is sold as a dietary supplement in the US[citation needed] and as a medication in other countries.[which?]

Mechanism of action

Noopept Box Front
Noopept blister pack

Noopept is not a racetam (due to not having a 2-oxo-pyrrolidine skeleton),[2] but is generally grouped together in the same category because it shares similar mechanisms of action with the racetam family, mainly modulation of the acetylcholine system, as well as modulation of AMPA receptors.[3] When compared to traditional racetams, it has been found to be, according to studies, 1000 times more potent than the prototypical racetam drug, piracetam.[4] Noopept is a prodrug for the endogenous peptide cycloprolylglycine.[5]

Pharmacokinetics

Peak plasma noopept concentrations of 13-33 μg/L are reached within one hour after a single 20 mg oral dose. The half-life averages about 1 hour in healthy individuals. It is mainly cleared renally as a series of metabolites produced by amide and ester hydrolysis, deacylation and aromatic hydroxylation. Noopept may be quantitated in biofluids by liquid chromatography with one of several different detection techniques.[6][7]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

Template:Antihyperkinetics

  1. PatentGenius.com http://www.patentgenius.com/patent/5439930.html
  2. Lua error in package.lua at line 80: module 'strict' not found.
  3. Lua error in package.lua at line 80: module 'strict' not found.
  4. Lua error in package.lua at line 80: module 'strict' not found.
  5. Lua error in package.lua at line 80: module 'strict' not found.
  6. S.S. Boiko, S.A. Korotkov, V.P. Zherdev et al. Interspecific differences of noopept pharmacokinetics. Eksp. Klin. Farmakol. 67: 40–43, 2004.
  7. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 10th edition, Biomedical Publications, Seal Beach, CA, 2014, p. 1524-1525. http://www.biomedicalpublications.com/noopept.pdf